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Managing direct oral anticoagulants in patients 
undergoing dentoalveolar surgery
J. P. Patel,*1,2 S. A. Woolcombe,3 R. K. Patel,1 O. Obisesan,3 L. N. Roberts,1 C. Bryant3 and R. Arya1
and published guidelines, endorsed by the 
British Society of Haematology, which has 
led to a standardised approach to patient 
management within this setting. These guide-
lines state that the INR should be assessed 
within 72 hours before the procedure and if 
below 4 then usually no specific intervention 
is required. The guidelines also suggest that 
the risk of bleeding should be minimised by 
the use of local haemostatic measures and 5% 
tranexamic acid mouthwash four times a day 
for 48 hours post-procedure.
In recent years, the anticoagulation landscape 
has changed with the availability of direct oral 
anticoagulants (DOACs), for example, apixaban, 
dabigatran, edoxaban and rivaroxaban.6 This 
raises the question of whether these agents 
require special management peri-procedurally. 
Given the current advice regarding oral VKA 
therapy, one might simply follow the course of 
action that is followed for VKAs, ie to advise the 
patient to continue as per usual and minimise 
the risk of bleeding with local haemostatic 
measures, as outlined previously. However, the 
DOACs have a rapid onset and offset of action 
Introduction
It is relatively common for patients who 
are anticoagulated to require dentoalveolar 
surgery, particularly dental extractions. In 
the RELY study,1 460 patients (2.5% of study 
cohort) required a dental procedure during 
the course of the trial. The risk of persistent 
bleeding complicating dental extraction in 
patients who are not receiving oral anticoagu-
lants is estimated to be 1%.2,3 In patients who 
are prescribed oral anticoagulants this risk is 
reported to increase to between 4% and 9%.2,4
In order to overcome inconsistencies that 
patients prescribed vitamin K antagonists 
(VKAs) experienced while undergoing den-
toalveolar procedures, Perry et al.5 compiled 
Our objective was to describe our experience of managing a cohort of adult patients prescribed direct oral anticoagulants 
(DOACs) undergoing dentoalveolar procedures between November 2012 and May 2016. Prior to conducting a procedure a 
formal assessment was made of each patient’s anticoagulation treatment. A specific plan was then formulated, balancing the 
risk of bleeding with the risk of thrombosis. Patients received a telephone consultation one week following treatment to assess 
any post-operative bleeding. Eighty-two patients underwent 111 oral surgical procedures, the majority of which were dental 
extractions. In the case of 35 (32%) procedures, advice was given to omit the DOAC, either before or after treatment. There 
was no bleeding following the majority of procedures. Persistent bleeding followed 15 (13.5%) procedures, of which 7 (6.3%) 
procedures required specific intervention. The majority of patients prescribed DOACs can undergo dentoalveolar procedures 
safely. Important considerations when planning treatment are: (i) when the patient usually takes their dose of DOAC, (ii) the 
time the procedure is performed and, (iii) when the DOAC is taken post-procedure. In our experience, if these factors are 
considered carefully, omission of DOAC doses is unlikely to be required for most patients.
relative to VKAs,7 which makes these agents 
different in a peri-procedural setting (Table 1). 
Additionally, measurement of anticoagulation 
intensity is not usually required or readily 
available for DOACs.
Based on the manufacturers’ recommenda-
tions, one might consider it prudent to ask the 
patient to omit a dose of a DOAC before the 
dentoalveolar procedure, in order to reduce 
the risk of bleeding. The rapid onset of action 
of the DOACs also requires careful considera-
tion. If a patient takes a dose of DOAC within 
four  hours of completing a dentoalveolar 
procedure they could be exposed to high anti-
coagulant activity in the early post-operative 
period. This may potentially increase the 
risk of bleeding, with peak concentrations of 
DOACs being reached within four hours of 
ingesting a dose.
During the past four years, as individual 
DOACs have become available worldwide, 
information on their use in the real-world 
population has been growing.9–11 There is, 
however, little available information regarding 
patients having dentoalveolar procedures while 
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Describes the first UK evaluation of undertaking 
dental extractions in patients prescribed DOACs.
Provides useful information on direct oral 
anticoagulants for other practitioners.
Key considerations are the time of last DOAC dose in 
relation to the dentoalveolar procedure and time of 
DOAC recommencement post-procedure.
In briefIn brief
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taking these agents. Recently Douketis et al.12 
reported the outcomes of patients who required 
a surgical intervention during the RELY trial. 
Four hundred and sixty patients in the study 
required a dental procedure, 455 elective pro-
cedures and five emergency procedures. The 
authors found that there were no differences in 
outcomes between the warfarin and dabigatran 
arms of the trial, although the risk of bleeding 
or thromboembolism was higher in patients 
having an urgent procedure compared to those 
patients having an elective procedure. 
As the use of DOACs has become more 
prevalent in the UK, they have received increas-
ing attention in the dental community.13–21 Early 
discussions focused on increasing the awareness 
of these agents, with more recent considerations 
concentrating on how to manage the agents 
peri-procedurally. The Scottish Dental Clinical 
Effectiveness Programme (SDCEP) published 
guidance on the management of dental patients 
taking anticoagulants or anti-platelet drugs in 
2015.22 To the best of our knowledge, this is 
the only guidance which formally addresses 
how DOACs might be managed in this 
specific setting. The guidance suggests that if 
the bleeding risk is low, treatment should be 
performed without interrupting the DOAC and 
that if the bleeding risk is high (according to 
a list of specified procedures), patients should 
be advised to miss or delay the morning dose 
before treatment. For both low and high risk 
procedures the guidance suggests treating early 
in the day, limiting the initial treatment area and 
assessing bleeding before continuing, staging 
extensive or complex procedures and actively 
considering suturing and packing. It also 
stipulates that patients should be given specific 
advice on when it might be safe to restart their 
DOAC. Additionally, the guidance recommends 
consulting a general medical practitioner or 
specialist for patients who have other relevant 
medical complications which may further 
increase the risk of bleeding, including liver, 
renal and bone marrow disorders. This guidance 
has only recently become available. We however 
have been managing patients on DOACs for the 
past four years. Our paper describes our clinical 
experience of conducting oral surgical proce-
dures in patients prescribed DOACs to date.
Methods
In our hospital, we began to prescribe DOAC 
therapy, according to licensed indications, 
in the summer of 2012. This followed NICE 
approval for dabigatran in the context of atrial 
fibrillation (AF)23 in line with the South London 
Stroke and Cardiac Network guidance.24 
We had no clinical experience of managing 
DOAC therapy during dentoalveolar surgery. 
Therefore the Department of Oral Surgery and 
the Department of Haematological Medicine 
decided to prospectively manage each patient 
on a case by case basis from November 2012, 
when the first patient prescribed a DOAC 
underwent an oral surgical procedure. This 
involved considering the patient’s past medical 
history, the indication for anticoagulation, any 
renal impairment and the risk of bleeding asso-
ciated with the procedure planned, along with 
the risk of thrombosis if anticoagulant therapy 
were to be temporarily stopped. In addition, 
patients had the anticoagulation intensity 
assessed (varying time after dose), before the 
procedure with a calibrated anti-Xa-assay 
for apixaban and rivaroxaban (STA-liquid 
anti-Xa assay [Diagnostica Stago, France]) 
and an ecarin time assay, calibrated for dabi-
gatran (STA-ECA II dabigatran chromogenic 
assay [Diagnostica Stago, France]). The results 
were reported back in ng/mL for the respec-
tive drug assayed. After consideration of the 
relevant information a specific plan was for-
mulated for each patient, including whether 
the DOAC should be simply continued as 
per usual, omitted, or the timing of DOAC 
administration altered. Furthermore, as we 
had no clinical experience of DOAC use in 
this setting, we conducted a telephone review 
for each patient, one week following the oral 
surgical procedure, to elucidate if any delayed 
post-operative bleeding had occurred.
If a patient did experience bleeding, infor-
mation regarding this was captured and cate-
gorised according to the following: (i) bleeding 
present, but no action required; (ii) required 
consultation in the dental unit, but no specific 
intervention required; (iii) required surgical 
Table 1  Key properties8 of the direct oral anticoagulants which are currently available for use in the UK
Pharmacokinetic 
parameter Dabigatran Apixaban Edoxaban Rivaroxaban
Bioavailability (%) 6 70 62 80
Peak onset (h) 1.5–2 3–4 1–2 2–4
Elimination half-life (h)* 12–14 12 10–14 7–11
Manufacturers’ 
recommendations on 
discontinuation before 
surgical procedure
If possible, dabigatran should be discontinued 
at least 24 hours before invasive or surgical 
procedures. In patients at higher risk of 
bleeding or in major surgery where complete 
haemostasis may be required, consider 
stopping dabigatran 2–4 days before surgery. 
Clearance of dabigatran in patients with renal 
insufficiency may take longer. This should be 
considered in advance of any procedures.
Dabigatran etexilate should be restarted after 
the invasive procedure or surgical interven-
tion as soon as possible provided the clinical 
situation allows and adequate haemostasis 
has been established.
Patients at risk for bleeding or patients at 
risk of overexposure, notably patients with 
moderate renal impairment (CrCL 30–50 mL/
min), should be treated with caution.
Apixaban should be stopped 
48 hours before a procedure 
with a moderate or high risk 
of bleeding and 24 hours 
before a procedure with a 
low risk of bleeding.
If anticoagulation must 
be discontinued to reduce 
the risk of bleeding with 
surgical or other procedures, 
edoxaban should be stopped 
as soon as possible and 
preferably at least 24 hours 
before the procedure.
If an invasive procedure 
or surgical intervention is 
required, rivaroxaban 20 mg 
should be stopped at least 
24 hours before the interven-
tion, if possible.
Manufacturers’ 
recommendations on 
restarting post-surgical 
procedure
Apixaban should be restarted 
after the invasive procedure 
or surgical intervention as 
soon as possible provided the 
clinical situation allows and 
adequate haemostasis has 
been established.
Edoxaban should be restarted 
after the surgical or other 
procedures as soon as 
adequate haemostasis has 
been established, noting 
that the time to onset of the 
edoxaban anticoagulant ther-
apeutic effect is 1–2 hours.
Rivaroxaban should be 
restarted as soon as possible 
after the invasive procedure 
or surgical intervention 
provided the clinical situation 
allows and adequate haemo-
stasis has been established 
as determined by the treating 
physician.
*assumes no renal impairment
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intervention (resuturing and haemostatic 
packing) and/or use of an antifibrinolytic; and 
(iv) required blood transfusion, replacement 
therapy or desmopressin.
Information on all patients was retrospec-
tively entered onto SPSS v20 and analysed. 
Descriptive statistics were used to analyse and 
present the results.
Results
During the time we have been collecting infor-
mation, 92 patients have been referred for oral 
surgical procedures to the unit, of which 82 
patients underwent 111 procedures while pre-
scribed a DOAC. The ten remaining patients 
referred were excluded because three  had 
discontinued DOAC therapy prior to the 
procedure, one was deemed medically unfit 
for the procedure and six did not attend for 
their planned treatment. Table 2 summarises 
the demographic information on the patients 
who did have a procedure while on DOAC 
therapy. In our unit the number of procedures 
conducted on patients prescribed concurrent 
DOAC has increased year on year, reflecting an 
increase in the use of DOACs in our locality. 
We undertook one procedure in 2012, 11 in 
2013, 18 in 2014, 50 in 2015 and 31 at the time 
of writing in May 2016.
Forty-six patients (56.1%) were prescribed 
DOAC for stroke prevention in the context 
of AF, 28 (34.1%) were prescribed DOAC for 
the acute and secondary prevention of venous 
thromboembolism (VTE), four patients (4.9%) 
were prescribed DOAC for other indications 
and in four cases (4.9%), the indication was 
not clear. Seventy-five (91.5%) patients had 
DOAC concentrations assayed before the 
procedure to assess anticoagulation intensity. 
Of these, 72 patients (96%) had concentrations 
considered in range, in line with published 
data. Three patients (4%) had concentrations 
suggestive of over-anticoagulation and in 
such cases advice was given to omit dosing of 
DOACs before the procedure, to account for 
this. Nine patients were prescribed concomitant 
anti-platelet therapy with their DOAC; three 
were prescribed aspirin, four were prescribed 
clopidogrel and two patients were prescribed 
a combination of clopidogrel and aspirin. Two 
patients were prescribed a regular non-steroidal 
anti-inflammatory drug (NSAID), ibuprofen 
and naproxen respectively. Twenty-one patients 
were prescribed a twice daily DOAC and the 
remaining 61 patients were taking rivaroxaban 
once daily. Twenty-eight patients took this in the 
Table 2  Demographic information on the patients who underwent a dentoalveolar procedure
Demographic information (N = 82) N (%) unless otherwise specified
Age, years – mean (min–max) 67.3 (19–93)
Female gender 36 (43.9)
Height, cm (sd) 168.4 (9.95)
Weight, kg (sd) 86.6 (23.3)
Calculated CrCl*, - mean mL/min (min-max) 82 (29– 224)
Concurrent anti-  platelet prescribed 9 (10.9)
Concurrent NSAID prescribed 2 (2.4)
DOAC prescribed
Rivaroxaban 20 mg od 46 (56)
Rivaroxaban 15 mg od 15 (18)
Apixaban 5 mg bd 4 (5)
Apixaban 2.5 mg bd 7 (9)
Dabigatran 150 mg bd 2 (2)
Dabigatran 110 mg bd 7 (9)
Other DOAC dose (rivaroxaban 10mg bd) 1 (1)
*Based on adjusted body weight, when the patient was obese
Table 3  Procedure and anaesthesia type
Procedure conducted N (%)
Type of procedure
Routine dental extraction 82 (73.9)
Surgical dental extraction 23 (20.7)
Other*  6 (5.4)
Single or multiple
Single 53 (47.7)
Multiple 58 (52.3)
Anaesthesia type
Local infiltration only 73 (66)
Inferior dental (ID) block 38 (34)
*This was excisional biopsy (x1), surgical dental extraction and incision and drainage (x1), enucleation of cyst (x1), routine 
extraction of upper left second premolar root and curettage of apical granulation tissue (x1), labial salivary gland biopsy (x1), 
incisional biopsy of buccal mucosa (x1) 
Table 4  Specific advice given to patients before the procedure
Advice given n (%)
Continue DOAC as per usual 68 (61)
Omit a single dose before procedure 26 (23)
Omit a single dose before and after procedure 5 (5)
Omit a single dose after procedure 3 (3)
Delay the evening dose after procedure 8 (7)
Omit for 2 days before procedure and re-start the evening following procedure 1 (1)
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morning, three in the afternoon and 30 patients 
took their rivaroxaban in the evening. The 111 
procedures that the 82 patients underwent are 
summarised in Table 3.
In our cohort specific advice was given to 
omit doses of DOAC before and/or after the 
procedure for 35 (32%) procedures, and for 
eight (7%) procedures advice was given to 
delay the evening dose after the procedure. 
Table 4 describes in categories the advice given.
Interestingly, 14 patients (15 [13.5%] proce-
dures) did not follow the pre-operative advice 
and/or post-operative advice given, either 
omitting doses when advised to continue as 
usual or omitting more doses of DOAC than 
recommended.
Over time and with increasing experi-
ence, advice to omit doses of DOACs became 
less frequent and whenever possible, simply 
adjusting the timing of DOACs on the day of 
the procedure became more prevalent.
On the day of the procedure, the median 
time that had elapsed between the last dose 
of DOAC and the start of the procedure was 
15  hours (inter-quartile range 8 – 20). No 
patients experienced bleeding or haematoma at 
the site of inferior dental (ID) block injection.
Persistent bleeding occurred following 15 
(13.5%) procedures. For six procedures the 
bleeding was trivial and no specific action 
was required. Following two procedures 
specific consultation in the oral surgery unit 
was required but no intervention was imple-
mented. Intervention to arrest bleeding, either 
surgical (resuturing and haemostatic packing) 
and/or use of an antifibrinolytic agent, was 
required following the remaining seven (6.3%) 
procedures.
The details of the six patients who had 
bleeding requiring intervention are provided 
online as supplementary information Table 1.
Discussion
This paper describes the experience in our 
centre of managing patients prescribed DOACs 
as they underwent dentoalveolar procedures 
over the past four years. To the best of our 
knowledge, this is one of the first evaluations 
of using DOACs in a large cohort in this setting 
and provides a valuable insight into how best to 
manage patients undergoing these procedures.
Due to lack of guidance and practical expe-
rience regarding the impact of continuing 
DOACs peri-procedurally, our initial approach 
was to minimise drug exposure at the time of 
surgery. This involved omitting a dose/doses 
on the day of treatment, before and/or after the 
procedure, indication permitting. However, 
with increasing experience it became apparent 
that such a conservative approach was not 
required if the risk of bleeding was low. In 
such cases continuing the DOAC as per usual 
became the recommended management. Such 
an approach has recently been endorsed by the 
SDCEP guidance. The experience we have to 
date suggests that such advice is sensible and 
we now most often follow this approach for new 
patients referred for treatment, providing they 
do not have additional risk factors for bleeding.
In our cohort, post-operative bleeding 
followed 15 (13%) procedures, of which 
six (5%) procedures had minor or trivial 
bleeding requiring no specific intervention. 
Consultation in the oral surgery unit was 
required following two (2%) procedures but 
no intervention was necessary. Specific inter-
vention was required to arrest bleeding which 
occurred following seven (6%) procedures. 
This compares favourably with the notable 
studies in the literature to date and those 
reported with VKAs. Gomez-Moreno et al.24 
reported a series of 29 patients who had dental 
implant surgery while prescribed dabigatran. 
Patients had their implants inserted 12 hours 
after the last dose of dabigatran. Following 
surgery patients were given gauzes impreg-
nated with 5% tranexamic acid to bite on for 
30–60 minutes. Dabigatran was re-started 
eight hours after treatment. Two episodes of 
minor bleeding were reported (7%) which were 
managed with additional gauzes impregnated 
with 5% tranexamic acid. Another study from 
the same group of authors25 reported on 18 
patients who had dental implant surgery while 
prescribed rivaroxaban therapy, without any 
interruption or modification of the rivaroxa-
ban regime. Following surgery all patients were 
given gauzes impregnated with 5% tranexamic 
acid to bite on for 30–60 minutes. One patient 
(5.5%) presented the day following surgery 
with moderate bleeding which was success-
fully managed with gauzes impregnated with 
5% tranexamic acid. In another dental implant 
surgery setting, Clemm et al.26 analysed the 
post-operative bleeding risk of 117 patients 
continuing their anticoagulation therapy and 
undergoing implant surgery and bone grafting 
procedures. There were four cases of bleeding 
(3.4%) in the antithrombotic cohort of 101 
patients, with no reports of post-operative 
bleeding in the 16 patients prescribed DOACs. 
More recently, Mauprivez and colleagues27 
have compared the incidence of post-operative 
bleeding events following dental extrac-
tions between patients prescribed DOACs 
(31 patients) and VKAs (20 patients). Five 
patients taking DOACs had seven bleeding 
episodes and four patients taking VKAs had 
five bleeding episodes. The authors of this 
study conclude that dental procedures can 
be performed safely in an outpatient facility 
in patients prescribed a DOAC, by applying 
local haemostatic measures, without interrupt-
ing or modifying the DOAC. In the studies 
published to date, local haemostatic measures 
were applied. In our cohort, local haemostatic 
measures were similarly applied and positive 
outcomes were observed in most cases. This 
demonstrates that in simple cases the DOACs 
can be safely managed in the context of den-
toalveolar surgery, providing careful consid-
eration is given to the timing of the last dose in 
relation to the surgical procedure and the time 
of re-commencement of the DOAC. However, 
for those cases which are complicated by the 
patient being frail elderly, having relevant 
medical co-morbidities or taking concomitant 
anti-platelet therapy, dental surgeons should 
seek specialist medical advice.
In this new era of oral anticoagulation it is 
important that the dental surgeon is aware that 
a patient is taking a DOAC. Early in our study 
there was one case where the dental surgeon 
was unaware of the prescription of a DOAC 
and in this instance the patient experienced 
bleeding post-operatively. Recently a study 
conducted in Scotland has highlighted this 
problem outside of the dental setting,28 with the 
authors demonstrating through survey data a 
lack of understanding and awareness of these 
newer anticoagulants and their specific proper-
ties among prescribers in both primary and 
secondary care, including independent nurse 
and pharmacist prescribers. This highlights the 
importance of awareness of these agents and 
that they should command the same respect 
as warfarin and other VKAs.
The rapid onset of action of the DOACs 
needs careful consideration in the peri-
procedural setting. For patients prescribed a 
once daily DOAC, following advice to take 
their usual dose in the morning, we aimed to 
complete the procedure late in the afternoon 
when the concentration was decreasing, in the 
knowledge that the next dose of DOAC would 
not be taken until the following day. However, 
for those taking twice daily DOAC, conducting 
a procedure late in the afternoon could lead 
to the patient taking their evening dose soon 
after the completion of treatment. Therefore, 
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careful consideration should be given to 
when the DOAC should be re-commenced. 
Furthermore, patients should be given clear 
instructions on what to do if they experience 
bleeding when they get home. In other words, 
a form of safety netting is required.
In our cohort, 14 patients (15 procedures), 
did not follow the specific instructions given to 
them on omitting doses before the procedure, 
and/or after treatment. We found that patients 
tended to omit more doses than advised and if 
not identified this could lead a surgeon into a 
false sense of security when little or no bleeding 
occurs. Dental surgeons should be mindful of 
this. To the best of our knowledge, no patients 
suffered a pathological thrombotic event as a 
result of omitting/delaying doses of a DOAC.
Finally, a sizeable number of patients in 
our cohort were older adults. It is expected 
that the pharmacokinetic properties of the 
DOACs are likely to be altered in the very 
elderly, particularly those classed as frail. 
Continuing the DOAC as per usual may lead 
to problems with bleeding and consideration 
should therefore be given to omitting one or 
two doses if the clinical situation allows. The 
majority of patients in our study had their 
renal function checked in order to assess the 
potential for accumulation of the DOAC. We 
found that patients with renal impairment 
had already had the DOAC dose adjusted to 
account for this.
Based on our experience, dentists conduct-
ing oral surgical procedures might anticipate 
a post-operative bleeding rate, requiring 
additional local measures for haemostasis in 
the region of 6%. Patients at increased risk 
of bleeding (frail elderly, those with relevant 
medical complications or on concurrent anti-
platelet therapy and those requiring extensive 
surgical treatment) should be considered for 
referral to secondary care for specialist input. 
In these cases, any decision to alter the DOAC 
regime should be made on a case by case basis, 
balancing those factors likely to increase the 
risk of bleeding with the risk of thrombosis.
The results of our study should be consid-
ered in the context of its limitations. They are 
limited by the lack of a control arm and by 
virtue of being from a single centre. Despite 
these limitations our report provides an early 
valuable insight into the practical management 
of patients prescribed DOACs undergoing oral 
surgical procedures.
In conclusion, it is possible to safely conduct 
dentoalveolar procedures for patients prescribed 
concurrent DOACs. In order to minimise 
post-operative bleeding and complication, it 
is important to consider the time the DOAC 
is usually ingested and when the procedure 
is planned. Dental surgeons should aim to 
undertake the procedure when peak DOAC 
concentrations have subsided ie, 5–6 hours post 
last dose. Current SDCEP guidance suggests 
achieving this by delaying the morning dose 
of a DOAC for procedures with a high risk of 
bleeding. We endorse this recommendation 
as it avoids having to treat patients in the late 
afternoon when there is limited time to manage 
persistent bleeding. Careful consideration 
should also be given to when the DOAC is re-
commenced. We suggest waiting a minimum 
of four to six hours after the procedure and that 
haemostasis should be secure. We would also 
advise that local measures to promote haemo-
stasis, ie, haemostatic packing and soft tissue 
suturing, are used in every case. Patients at 
high risk of bleeding, should be considered for 
referral to specialist units for their procedures. 
Further clinical experience and controlled 
cohort studies will determine the optimum peri-
procedural strategy for managing this growing 
cohort of patients.
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